Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2020

View Archived Issues

Myelin regulatory factor helps out pancreatic cancer cells

Angiotensin inhibitors for AD prevention

Phase II study of mavrilimumab in giant cell arteritis meets efficacy endpoints

Chiba Prefecture patents new compounds targeting mitochondrial DNA mutations

Cortexyme discloses Porphyromonas gingivalis RgpB inhibitors

University of Maryland synthesizes new Mcl-1 and Bcl-2 dual inhibitors

Inflammatory response gene identified in sepsis

Anlotinib plus pemetrexed beneficial in platinum-resistant epithelial ovarian cancer

University of California identifies new EGFR inhibitors

Early clinical data presented for rebastinib

Fulcrum Therapeutics discovers new EED inhibitors

Nivolumab + cabozantinib in first-line RCC: CheckMate 9ER suggests new standard of care

Phase I data presented for Sym-021 as monotherapy or in combination with Sym-022 or Sym-023

Gut-derived LEAP2 fragment demonstrates beneficial metabolic effects on RYGB

Activity seen in phase Ib study of sintilimab and niraparib in advanced solid tumors

Zenith Epigenetics signs CRADA with NCI to develop ZEN-3694 for cancer

Amgen reports topline phase II results with sotorasib in KRAS G12C-mutant advanced NSCLC

Phase II study of neflamapimod for dementia with Lewy bodies meets primary endpoint

NexImmune initiates phase I/II trial of NEXI-002 in multiple myeloma

Avrobio licenses gene therapy for Hunter's syndrome from University of Manchester

Eureka Therapeutics begins phase I/II trial of T-cell therapy in HCC

Pharmacokinetic data on AbFero's iron chelator SP-420 support planned phase I/II study

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Kymera’s IRF5 degrader shows potential in IBD treatment
BioWorld Science
At the recently concluded Digestive Disease Week, researchers from Kymera Therapeutics Inc. presented preclinical efficacy data on KT-579, a selective oral IRF5...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...